The Phase 3 LITESPARK‑022 trial reported that combining belzutifan, a HIF‑2α inhibitor, with pembrolizumab significantly improved disease‑free survival in high‑risk clear‑cell renal cell carcinoma (ccRCC) patients after surgery. The sponsor presented data showing extended cancer‑free intervals versus control, supporting a potential adjuvant application of the HIF‑2α inhibitor alongside PD‑1 blockade. Results were disclosed by the trial sponsor and align with broader efforts to move targeted small molecules into adjuvant oncology settings where immune checkpoint inhibitors already play a role. The combination’s safety profile and impact on overall survival remain key endpoints for regulators and clinicians. Oncology teams and regulatory strategists should track full dataset releases and planned label updates, as positive adjuvant data could expand belzutifan’s market beyond current indications and affect standard‑of‑care sequencing in localized, high‑risk ccRCC.